Skip to main content

Table 7 Included studies—nonsurgical treatment of peri-implantitis: adjunctive antiseptic therapy

From: Efficacy of alternative or adjunctive measures to conventional treatment of peri-implant mucositis and peri-implantitis: a systematic review and meta-analysis

Publication Design Population Case definition Period Test Control Mean (SD) outcome
Machtei et al. [23] Multicentre RCT, parallel 60 patients PD = 6–10 mm and BOP + radiographic bone loss 6 months OHI + ultrasonic debridement + matrix containing 2.5-mg CHX chips (i.e. up to 4 per implant site) OHI + ultrasonic debridement + biodegradable crosslinked gelatin matrix chip Test
   77 implants    Repeated application at sites with PD ≥6 mm at 2, 4, 6, 8, 12 and 18 weeks Repeated application at sites with PD ≥6 mm at 2, 4, 6, 8, 12 and 18 weeks BOP: 100 (0.0) (BL) to 42.5 (50.0) % (6 months, subject level)
        PD: 7.6 (1.1) (0.0) to 5.47 (1.86) mm (6 months, subject level)
        Control
        BOP: 100 (0.0) (BL) to 54.5 (50.5) % (6 months, subject level)
        PD: 7.21 (1.08) (BL) to 5.48 (1.25) mm (6 months, subject level)
        BOP and PD reductions at 6 months not sign. different between groups
  1. BL baseline, BOP bleeding on probing, CHX chlorhexidine digluconate, OHI oral hygiene instructions, PD probing pocket depth, RCT randomized controlled clinical study